In this largest trial of GLP1 agonists in MASH to date, efficacy analysis (which included the first 800 patients) demonstrated that once weekly Semaglutide was superior to placebo in reducing steatohepatitis without worsening of fibrosis (62.9% vs 34.1%, estimated difference in responder proportions (EDP) 28.9% [95% CI 21.3; 36.5], p < 0.001) and fibrosis improvement by ≥ 1 stage without worsening of steatohepatitis (37% vs 22.5%, EDP 14.4% [95% CI 7.5; 21.4], p < 0.001) at the 72-week time point. Here, GCG is linked to metabolic dysfunction-associated steatohepatitis.